ASCO GI 2021 | KEYNOTE-240: pembrolizumab in advanced HCC

Philippe Merle, MD, PhD, Croix-Rousse Hospital, Lyon, France, provides an update on the KEYNOTE-240 study (NCT02702401), a Phase III trial evaluating pembrolizumab, an anti-PD-1 antibody, versus placebo in patients with advanced hepatocellular carcinoma (HCC) that were previously treated with sorafenib, a tyrosine kinase inhibitor. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).